- Home
- OCSL vs SYRE Comparison
OCSL vs SYRE Comparison
Compare OCSL & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- SYRE
- Stock Information
- Founded
- OCSL 2007
- SYRE 2013
- Country
- OCSL United States
- SYRE United States
- Employees
- OCSL N/A
- SYRE N/A
- Industry
- OCSL Finance: Consumer Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- SYRE Health Care
- Exchange
- OCSL Nasdaq
- SYRE Nasdaq
- Market Cap
- OCSL 1.1B
- SYRE 1.1B
- IPO Year
- OCSL 2008
- SYRE 2016
- Fundamental
- Price
- OCSL $12.93
- SYRE $19.00
- Analyst Decision
- OCSL Hold
- SYRE Strong Buy
- Analyst Count
- OCSL 6
- SYRE 6
- Target Price
- OCSL $15.20
- SYRE $57.60
- AVG Volume (30 Days)
- OCSL 873.5K
- SYRE 848.9K
- Earning Date
- OCSL 11-18-2025
- SYRE 11-06-2025
- Dividend Yield
- OCSL 12.38%
- SYRE N/A
- EPS Growth
- OCSL N/A
- SYRE N/A
- EPS
- OCSL 0.55
- SYRE N/A
- Revenue
- OCSL $334,099,000.00
- SYRE N/A
- Revenue This Year
- OCSL N/A
- SYRE N/A
- Revenue Next Year
- OCSL N/A
- SYRE N/A
- P/E Ratio
- OCSL $23.64
- SYRE N/A
- Revenue Growth
- OCSL N/A
- SYRE N/A
- 52 Week Low
- OCSL $12.44
- SYRE $10.91
- 52 Week High
- OCSL $16.66
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- OCSL 44.79
- SYRE 59.91
- Support Level
- OCSL $12.44
- SYRE $16.04
- Resistance Level
- OCSL $12.73
- SYRE $21.51
- Average True Range (ATR)
- OCSL 0.23
- SYRE 1.31
- MACD
- OCSL -0.01
- SYRE 0.42
- Stochastic Oscillator
- OCSL 66.14
- SYRE 58.31
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.